# Phathom Pharmaceuticals, Inc.: Form 10-K/A for the period ended Dec 31, 2023

- Company: [Phathom Pharmaceuticals, Inc.](/companies/phat.md) (CIK 1783183)
- Form: 10-K/A
- Filed: 2024-06-14
- Accepted by EDGAR: Jun 14, 2024, 16:05 ET
- Period: 2023-12-31
- Accession: 0000950170-24-073629
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1783183/000095017024073629/phat-20231231.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1783183/000095017024073629/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2023-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 12 months, 2023-01-01 to 2023-12-31 | $682.0k | us-gaap:Revenues |
| Cost of revenue | 12 months, 2023-01-01 to 2023-12-31 | $167.0k | us-gaap:CostOfRevenue |
| Gross profit | 12 months, 2023-01-01 to 2023-12-31 | $515.0k | us-gaap:GrossProfit |
| Research and development | 12 months, 2023-01-01 to 2023-12-31 | $49.9m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 12 months, 2023-01-01 to 2023-12-31 | $117.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 12 months, 2023-01-01 to 2023-12-31 | −$167.3m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months, 2023-01-01 to 2023-12-31 | $42.0m | us-gaap:InterestExpense |
| Income tax | 12 months, 2023-01-01 to 2023-12-31 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months, 2023-01-01 to 2023-12-31 | −$201.6m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months, 2023-01-01 to 2023-12-31 | −$3.93 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months, 2023-01-01 to 2023-12-31 | −$3.93 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months, 2023-01-01 to 2023-12-31 | 51,289,092 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months, 2023-01-01 to 2023-12-31 | −$137.6m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months, 2023-01-01 to 2023-12-31 | $1.6m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2023-12-31 | $381.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2023-12-31 | $397.4m | us-gaap:AssetsCurrent |
| Total assets | at 2023-12-31 | $413.8m | us-gaap:Assets |
| Current liabilities | at 2023-12-31 | $38.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2023-12-31 | $486.6m | us-gaap:Liabilities |
| Long-term debt | at 2023-12-31 | $137.8m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2023-12-31 | $0 | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2023-12-31 | −$72.8m | us-gaap:StockholdersEquity |

## Controls and procedures

As filed, 4,294 characters.

### Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our periodic and current reports that we file with the SEC is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives. In reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. In addition, the design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, control may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

Our management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act as of the end of the period covered by this annual report. Based on such evaluation, our principal executive officer and principal financial officer have concluded that as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

### Management’s Annual Report on Internal Control Over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act). Internal control over financial reporting is a process designed under the supervision and with the participation of our management to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America. Management conducted an assessment of the effectiveness of our internal control over financial reporting based on the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control—Integrated Framework (2013 Framework). Based on this assessment, our management concluded that, as of December 31, 2023, our internal control over financial reporting was effective.

### Attestation Report of the Registered Public Accounting Firm

This annual report on Form 10-K/A does not include an attestation report of our registered public accounting firm due to an exemption provided by the JOBS Act for “emerging growth companies.”

### Changes in Internal Control Over Financial Reporting

During the quarter ended December 31, 2023, we implemented processes and internal controls to record product revenue, cost of product revenues, accounts receivable, and inventory as a result of the FDA approval and the U.S commercial launch of VOQUEZNA, VOQUEZNA TRIPLE PAK, and VOQUEZNA DUAL PAK. The implementation of these processes resulted in material changes to our internal controls over financial reporting. There were no other changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act), identified in connection with the evaluation of such internal control that occurred during the fourth quarter ended December 31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Filed Jun 14, 2024.
Source: SEC EDGAR, the filing index for accession 0000950170-24-073629. Last ingested by Listed: Nov 2, 2026, 17:47 ET. No prices; not investment advice.